Columbia University

Xiaoming Xu

Donald W Landry

Shi-Xian Deng

Shixian Deng

Owen Anthony O'Connor

Suzanne Lentzsch

Thomas Diacovo

Mark Lipstein

Shirong Li

Jing Fu

Changchun Deng

Compounds and methods for treatment of cancers such as multiple myeloma by inhibition of germinal center kinase.

Compounds, pharmaceutical formulations, and methods for treatment of cancer

In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and &#x3b4;, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma. 

Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia

The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to administration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.

Compounds for reducing c-Myc in c-Myc overexpressing cancers background

Growing community of inventors

Fair Lawn, NJ, United States of America

Xiaoming Xu